Search
Duloxetine
go.drugbank.com/drugs/DB00476ApprovedInvestigationalDuloxetine continues to be investigated for the treatment of pain in cancer, surgery, and more. … [A178741] Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: TQ INMOX 60 MG CAPSULAS, NOVAFLEX® 30MG CAPSULAS DE LIBERACION RETARDADATibolone
go.drugbank.com/drugs/DB09070ApprovedInvestigationalIt has been used in Europe for almost 2 decades, primarily for the prevention of postmenopausal osteoporosis and the treatment of post-menopausal symptoms [L1720]. … Tibolone is approved in 90 countries to manage menopausal symptoms and in 45 countries to prevent the development of osteoporosis [L1876].
Categories: Sex Hormones and Modulators of the Genital SystemDarvadstrocel
go.drugbank.com/drugs/DB16581ApprovedInvestigationalWithdrawn[L39759] It is the first mesenchymal stem cell therapy approved in Europe for this therapeutic indication. … [A244524] Darvadstrocel was first approved by the European Commission on March 23, 2018, under the brand name Alofisel.
Mifamurtide
go.drugbank.com/drugs/DB13615ApprovedInvestigationalMifamurtide is marketed in Europe as Mepact for intravenous infusion. … In a large, randomized, open-label, multicenter, phase III trial, the treatment of mifamurtide in conjunction with three- or four-drug combination chemotherapy (doxorubicin, cisplatin, and high-dose methotrexate
Abaloparatide
go.drugbank.com/drugs/DB05084ApprovedInvestigational[L740] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended abaloparatide be granted marketing authorization in Europe [L43552] and the drug was fully authorized … by the European Commission on December 19, 2022.
Lonapegsomatropin
go.drugbank.com/drugs/DB16220ApprovedInvestigational[L36380] It was later approved by the European Commission on 13 January 2022.[L39900] … 11.5 kg, with growth failure due to insufficient growth hormone secretion.
Nicorandil
go.drugbank.com/drugs/DB09220ApprovedInvestigationalWithdrawnNicorandil is an orally efficacious vasodilatory drug and antianginal agent marketed in the UK, Australia, most of Europe, India, Philippines, Japan, South Korea, and Taiwan. … It is shown to dilate normal and stenotic coronary arteries and reduces both ventricular preload and afterload [A20325].
Nicoboxil
go.drugbank.com/drugs/DB12911ApprovedWithdrawnSuch combination topical analgesics are only available for purchase and use (for humans) in some parts of Europe and Asia, like Germany and Australia [F11, F16]. … and capability to be used as an alternative musculoskeletal pain therapy option with less systemic side effects when compared to the oral non-steroidal anti-inflammatory drugs and opioids that may be
Sodium zirconium cyclosilicate
go.drugbank.com/drugs/DB14048ApprovedInvestigational[L2933] Approval of the medication is supported by data from three double-blind, placebo-controlled trials and two open-label trials which showed that the onset of action was approximately 1.0 hour and … [L2933] The treatment effect was maintained for up to 12 months.[L2933]
Parathyroid hormone
go.drugbank.com/drugs/DB05829ApprovedInvestigationalPreotact is used in the treatment of osteoporosis in postmenopausal women at high risk of osteoporotic fractures and is marketed in Europe by Nycomed. … The name Preos and the New Drug Application is pending approval by the U.S. Food and Drug Administration (FDA).